These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 21616443)

  • 1. [Ongoing debates on localized prostate cancer: epidemiology, screening and stratification].
    Audenet F; Rouprêt M
    Prog Urol; 2011 May; 21 Suppl 3():S75-9. PubMed ID: 21616443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prostate cancer screening (III): risk factors, natural history, course without treatment. Characteristics of detected cancers].
    Villers A; Soulié M; Haillot O; Boccon-Gibod L
    Prog Urol; 1997 Sep; 7(4):655-61. PubMed ID: 9410329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.
    Eggener SE; Scardino PT; Carroll PR; Zelefsky MJ; Sartor O; Hricak H; Wheeler TM; Fine SW; Trachtenberg J; Rubin MA; Ohori M; Kuroiwa K; Rossignol M; Abenhaim L;
    J Urol; 2007 Dec; 178(6):2260-7. PubMed ID: 17936815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families.
    Matikainen MP; Schleutker J; Mörsky P; Kallioniemi OP; Tammela TL
    Clin Cancer Res; 1999 Jun; 5(6):1275-9. PubMed ID: 10389909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancers of the prostate, penis, and testicles: epidemiology, prevention, and treatment.
    Stotts RC
    Nurs Clin North Am; 2004 Jun; 39(2):327-40. PubMed ID: 15159183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Epidemiology, diagnosis and prognosis of localized prostate cancer: what's new?].
    Drouin SJ; Rouprêt M
    Prog Urol; 2009 Apr; 19 Suppl 1():S3-7. PubMed ID: 19465334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology, diagnosis and treatment of prostate cancer.
    Newman J
    Radiol Technol; 1996; 68(1):39-64; quiz 65-8. PubMed ID: 8880970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating localized prostate cancer and identifying candidates for focal therapy.
    Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
    Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE).
    Meng MV; Elkin EP; Latini DM; Duchane J; Carroll PR
    J Urol; 2005 May; 173(5):1557-61. PubMed ID: 15821485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Explaining the race difference in prostate cancer stage at diagnosis.
    Jones BA; Liu WL; Araujo AB; Kasl SV; Silvera SN; Soler-Vilá H; Curnen MG; Dubrow R
    Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2825-34. PubMed ID: 18829446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis, management and screening of early localised prostate cancer.
    Selley S; Donovan J; Faulkner A; Coast J; Gillatt D
    Health Technol Assess; 1997; 1(2):i, 1-96. PubMed ID: 9414541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK.
    Mokete M; Shackley DC; Betts CD; O'Flynn KJ; Clarke NW
    BJU Int; 2006 Feb; 97(2):266-9. PubMed ID: 16430626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate biopsy: who, how and when. An update.
    Djavan B; Milani S; Remzi M
    Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen.
    Labrie F; Candas B; Cusan L; Gomez JL; Diamond P; Suburu R; Lemay M
    Urology; 1996 Feb; 47(2):212-7. PubMed ID: 8607237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen testing and prostate cancer screening.
    Djavan B; Eckersberger E; Finkelstein J; Sadri H; Taneja SS; Lepor H
    Prim Care; 2010 Sep; 37(3):441-59, vii. PubMed ID: 20705192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The epidemiology of prostate cancer].
    Rébillard X; Tretarre B; Villers A
    Rev Prat; 2003 Dec; 53(20):2224-8. PubMed ID: 15018075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prostate cancer primer.
    Gray M
    Urol Nurs; 2002 Jun; 22(3):151-67; quiz 172. PubMed ID: 12087789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer.
    Ishkanian AS; Zafarana G; Thoms J; Bristow RG
    Acta Oncol; 2010 Oct; 49(7):888-94. PubMed ID: 20590366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.
    Platz EA; Leitzmann MF; Rifai N; Kantoff PW; Chen YC; Stampfer MJ; Willett WC; Giovannucci E
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1262-9. PubMed ID: 15894683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.